Alpha 2.0
Login Register
» Authors » Mattias Ekstedt

Mattias Ekstedt

Explore the profile of Mattias Ekstedt including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 109
Citations 5212
Followers 0
Related Specialties
Gastroenterology
General Medicine
Endocrinology
Top 10 Co-Authors
Stergios Kechagias
Patrik Nasr
Hannes Hagstrom
Per Stal
Peter Lundberg
Quentin M Anstee
Vlad Ratziu
Rolf Hultcrantz
Jorn M Schattenberg
Elisabetta Bugianesi
Published In
J Hepatol
Scand J Gastroenterol
Liver Int
JHEP Rep
Hepatology
Affiliations
Soon will be listed here.
Recent Articles
1.
Clinically available predictors of obstructive sleep apnoea requiring treatment in type 2 diabetes patients in primary care
Agholme J, Ahtola K, Toll E, Carlhall C, Henriksson P, Kechagias S, et al.
Sci Rep . 2025 Mar; 15(1):8710. PMID: 40082634
Obstructive sleep apnoea is a common yet frequently underdiagnosed condition in patients with type 2 diabetes, particularly in primary care. Early detection is important, as untreated sleep apnoea may contribute...
2.
Role of noninvasive tests on the prediction of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without cirrhosis: a systematic review and meta-analysis of aggregate and individual patient data
Siriwong N, Sriphoosanaphan S, Decharatanachart P, Yongpisarn T, Kerr S, Treeprasertsuk S, et al.
Eur J Gastroenterol Hepatol . 2025 Feb; 37(3):358-369. PMID: 39919008
Background: Nonalcoholic fatty liver disease (NAFLD) has been identified as an emerging risk factor for hepatocellular carcinoma (HCC). Identifying non-cirrhotic NAFLD patients at risk for HCC is crucial. We aimed...
3.
Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLD
Vali Y, Dijk A, Lee J, Boursier J, Ratziu V, Yunis C, et al.
Liver Int . 2025 Jan; 45(2):e16240. PMID: 39865358
Background And Aims: The performance of non-invasive liver tests (NITs) is known to vary across settings and subgroups. We systematically evaluated whether the performance of three NITs in detecting advanced...
4.
Forty years of successful national research collaboration in liver disease - the Swedish experience
Bergquist A, Ekstedt M, Hagstrom H, Jarnerot G, Lindgren S, Nilsson E, et al.
Scand J Gastroenterol . 2024 Nov; 59(12):1314-1321. PMID: 39485016
Aim: Sweden has historically provided a fruitful arena for research in clinical medicine. We here share 40 years of experience of collaboration in the Swedish hepatology research group (SWEHEP) (https://www.swehep.se)....
5.
Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic metabolic dysfunction-associated steatotic liver disease
Shang Y, Akbari C, Dodd M, Zhang X, Wang T, Jemielita T, et al.
Hepatology . 2024 Aug; PMID: 39110990
Background And Aims: Noninvasive biomarkers provide prognostic information for the development of major adverse liver outcomes (MALOs) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), but the predictive value...
6.
Performance of novel collagen turnover biomarkers to detect increased liver stiffness in MASLD
Hegmar H, Wiggers T, Nasr P, Vessby J, Kechagias S, Nyhlin N, et al.
J Intern Med . 2024 Jul; 296(2):177-186. PMID: 38959258
Background: Cleavage products from collagen formation and degradation hold potential as first-line biomarkers for the risk of advanced fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we...
7.
Liver fibrosis is associated with left ventricular remodeling: insight into the liver-heart axis
Edin C, Ekstedt M, Karlsson M, Wegmann B, Warntjes M, Swahn E, et al.
Eur Radiol . 2024 May; 34(11):7492-7502. PMID: 38795131
Objective: In nonalcoholic fatty liver disease (NAFLD), liver fibrosis is the strongest predictor of adverse outcomes. We sought to investigate the relationship between liver fibrosis and cardiac remodeling in participants...
8.
A unified framework for prediction of liver steatosis dynamics in response to different diet and drug interventions
Simonsson C, Nyman E, Gennemark P, Gustafsson P, Hotz I, Ekstedt M, et al.
Clin Nutr . 2024 May; 43(6):1532-1543. PMID: 38754305
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a common metabolic disorder, characterized by the accumulation of excess fat in the liver, and is a driving factor for various...
9.
A physiologically-based digital twin for alcohol consumption-predicting real-life drinking responses and long-term plasma PEth
Podeus H, Simonsson C, Nasr P, Ekstedt M, Kechagias S, Lundberg P, et al.
NPJ Digit Med . 2024 May; 7(1):112. PMID: 38702474
Alcohol consumption is associated with a wide variety of preventable health complications and is a major risk factor for all-cause mortality in the age group 15-47 years. To reduce dangerous...
10.
Activin A levels in metabolic dysfunction-associated steatotic liver disease associates with fibrosis and the PNPLA3 I148M variant
Jonsson C, Bergram M, Kechagias S, Nasr P, Ekstedt M
Scand J Gastroenterol . 2024 Apr; 59(6):737-741. PMID: 38563432
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver condition worldwide. There is an urgent need to develop new biomarkers to assess disease severity and to...